Simulations Plus

Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share

Jill Fiedler-Kelly named President along with other promotions and key additions

New intra-articular injection route will expand the suite of drug delivery options available in GastroPlus®

Center for Veterinary Medicine to apply GastroPlus® to assess product bioequivalence in canines

Record quarter as revenues grow 16%, 9MoFY19 revenues up 13%
Board of Directors announces quarterly dividend of $0.06 per share

Enhancements include improved data handling and command line functionality

Conference Call to be on Wednesday, July 10, 2019, at 4:15 PM ET

Substantial update of NAFLD drug efficacy software offers a broad range of pathophysiology and over a thousand simulated patients for testing

User- and collaboration-driven functionality in version 9.7 expands the science of local and systemic exposure

Exciting New Features to its Pharmacometric Communication and Collaboration Platform

Japanese government organization to train reviewers to efficiently analyze PBPK model submissions

U.S. FDA Remains Committed to Streamline & Accelerate Drug Development using Model-Informed Drug Development (MIDD) technology

Shawn O’Connor, chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8.

Brings 35+ Years of Industry and Regulatory Expertise to Board

Center for Tobacco Products incorporates machine learning platform to assist toxicology research

New machine learning models and novel analysis methods address customer requests

Quarterly Revenues Up 15%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share

Conference Call to be on Tuesday, April 9, 2019, at 4:15 PM ET

Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months

New models for in vitro systems lead to improved inputs for GastroPlus® simulations